Literature DB >> 6968337

Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes.

E Fernandez-Cruz, B A Woda, J D Feldman.   

Abstract

Established subcutaneous Moloney sarcomas (MST-1) of large size and long duration were eliminated from syngeneic rats by intravenous infusion of varying numbers of specific syngeneic effector T lymphocytes. Spleen cells from BN rats in which tumor had regressed were cultured in an in vitro mixed lymphocyte tumor cell culture (MLTC) to augment cytotoxicity of effector cells. In the MLTC a T cell subset was expanded in response to MST-1 antigens and transformed into blast elements. With these changes, there was an increase in the W3/25 antigen on the T cell surface, a decrease of W3/13 antigen, and an increase in the number of T cells with Ia antigens. The subset associated with elimination of established tumors was a blast T cell W3/25+, W3/13+, as detected by monoclonal antibodies to rat T antigens. The W3/25+ subset was poorly cytotoxic in vitro for MST-1 and apparently functioned in vivo as an amplifier or helper cell in the tumor-bearing host. The W3/25- population was a melange of cells that included (W3/13+, W3/25-) T cells, null cells, Ig+ cells, and macrophages, and was associated with enhancement of tumor in vivo, suggesting the presence of suppressor cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968337      PMCID: PMC2185982          DOI: 10.1084/jem.152.4.823

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  71 in total

1.  Systemic transfer of tumor immunity: delayed hypersensitivity and suppression of tumor growth.

Authors:  H T Wepsic; B Zbar; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1970-04       Impact factor: 13.506

2.  An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice.

Authors:  J P Glynn; B L Halpern; A Fefer
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

3.  Effect of combination treatment with cyclophosphamide and isogeneic or allogeneic spleen and bone marrow cells in leukemic (L1210) mice.

Authors:  S Vadlamudi; M Padarathsingh; E Bonmassar; A Goldin
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

4.  Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.

Authors:  E Mihich
Journal:  Cancer Res       Date:  1969-04       Impact factor: 12.701

5.  Studies on the growth and regression of a transplantable Moloney sarcoma.

Authors:  A Fefer; J L McCoy; J P Glynn
Journal:  Cancer Res       Date:  1967-11       Impact factor: 12.701

6.  Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.

Authors:  A Fefer
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

7.  Immunotherapy of an intramuscular tumor in strain-2 guinea pigs: prevention of tumor growth by intradermal immunization and by systemic transfer of tumor immunity.

Authors:  H T Wepsic; B S Kronman; B Zbar; T Borsos; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1970-08       Impact factor: 13.506

8.  Immunotherapy of leukemia: the use of different classes of immune lymphocytes.

Authors:  P Alexander
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

9.  Inhibition of tumor growth by syngeneic spleen cell transfer.

Authors:  J C Fisher; W G Hammond
Journal:  Surg Forum       Date:  1966

10.  Treatment of a murine leukemia with spleen cells or sera from allogeneic mice immunized against the tumor.

Authors:  P Alexander; D I Connell; Z B Mikulska
Journal:  Cancer Res       Date:  1966-07       Impact factor: 12.701

View more
  48 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Toll-like receptors in tumor immunotherapy.

Authors:  Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas C Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

3.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

Authors:  H F Dullens; W Vuist; M Van der Maas; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.

Authors:  Weiqing Jing; Jill A Gershan; Bryon D Johnson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

Review 8.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

9.  In vitro activation of natural killer-like cytotoxicity by specifically in vivo primed T-helper lymphocytes in the rat.

Authors:  V Britten; R A Robins; R W Baldwin
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

Review 10.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.